Yahoo Finance EN

CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

Mar 07, 2026 &03100707202631; 12:10 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +65/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

CRISPR Therapeutics AG (CRSP) receives a Moderate Buy rating from Wall Street analysts, indicating cautious optimism about the company's gene-editing therapeutic pipeline and commercial prospects. This rating suggests potential upside with moderate risk, reflecting confidence in CRISPR technology applications while acknowledging execution and regulatory uncertainties.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

CRSP

CRSPStock

Expected to rise

Moderate Buy rating from Wall Street suggests analyst confidence in company's gene-editing therapeutic pipeline and commercial potential, supporting positive price momentum

↑

S&P 500

^GSPCIndex

Expected to rise

Biotech and healthcare sector strength from positive CRISPR sentiment may provide modest support to broader S&P 500 index

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating CRSP on dips toward support levels, targeting medium-term gains from pipeline advancement. Monitor clinical trial results and regulatory approvals as key catalysts; set stop-loss below recent support to manage downside risk from biotech volatility.

KEY SIGNALS

Moderate Buy consensus rating indicates balanced risk-rewardGene-editing technology validation by Wall StreetPotential regulatory and clinical trial catalysts aheadExecution risk remains on therapeutic development timeline

SECTORS INVOLVED

BiotechnologyHealthcareGene Therapy

Analysis generated on Mar 09, 2026 at 17:53 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

RELATED INTELLIGENCE